GPX4-IN-6
Based on 1 Customer Validation
GPX4-IN-6 (Compound C25) is a GPX4 covalent inhibitor with an IC50 value of 0.13 μM. GPX4-IN-6 (Compound C25) can induce ferroptosis for the research of triple-negative breast cancer (TNBC) .
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.65%
- CAS No.: 2922824-07-3
- Formule: C18H17BrFNO5
- Masse moléculaire:426.23
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Activité biologique
|
GPX4 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BT-549 | IC50 |
0.034 μM
Compound: C25
|
Antiproliferative activity against human BT-549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human BT-549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
|
[PMID: 37452764] |
| MDA-MB-231 | IC50 |
>20 μM
Compound: C25
|
Induction of ferroptosis in human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs in presence of glutathione by MTT assay
Induction of ferroptosis in human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs in presence of glutathione by MTT assay
|
[PMID: 37452764] |
| MDA-MB-231 | IC50 |
>20 μM
Compound: C25
|
Induction of ferroptosis in human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs in presence of N-acetyl-L-cysteine by MTT assay
Induction of ferroptosis in human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs in presence of N-acetyl-L-cysteine by MTT assay
|
[PMID: 37452764] |
| MDA-MB-231 | IC50 |
0.008 μM
Compound: C25
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
|
[PMID: 37452764] |
| MDA-MB-231 | IC50 |
0.018 μM
Compound: C25
|
Induction of ferroptosis in human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs in presence of autophagy inhibitor, 3-MA by MTT assay
Induction of ferroptosis in human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs in presence of autophagy inhibitor, 3-MA by MTT assay
|
[PMID: 37452764] |
| MDA-MB-231 | IC50 |
0.025 μM
Compound: C25
|
Induction of ferroptosis in human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs in presence of necrosis inhibitor, necrostatin-1 by MTT assay
Induction of ferroptosis in human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs in presence of necrosis inhibitor, necrostatin-1 by MTT assay
|
[PMID: 37452764] |
| MDA-MB-231 | IC50 |
0.03 μM
Compound: C25
|
Induction of ferroptosis in human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs in presence of apoptosis inhibitor, Z-VAD-FMK by MTT assay
Induction of ferroptosis in human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs in presence of apoptosis inhibitor, Z-VAD-FMK by MTT assay
|
[PMID: 37452764] |
| MDA-MB-231 | IC50 |
1.75 μM
Compound: C25
|
Induction of ferroptosis in human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs in presence of ferroptosis inhibitor, ferrostatin-1 by MTT assay
Induction of ferroptosis in human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs in presence of ferroptosis inhibitor, ferrostatin-1 by MTT assay
|
[PMID: 37452764] |
| MDA-MB-231 | IC50 |
1.85 μM
Compound: C25
|
Induction of ferroptosis in human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs in presence of deferoxamine by MTT assay
Induction of ferroptosis in human MDA-MB-231 cells assessed as cell viability incubated for 72 hrs in presence of deferoxamine by MTT assay
|
[PMID: 37452764] |
| MDA-MB-468 | IC50 |
0.012 μM
Compound: C25
|
Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 37452764] |
Chemical Information
-
CAS No. 2922824-07-3
-
Appearance Solid
-
Masse moléculaire 426.23
-
Formule C18H17BrFNO5
-
Color White to off-white
-
SMILES
O=C(CBr)N(C1=CC(OC)=C(F)C(OC)=C1)C2=CC(OCCO3)=C3C=C2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 50 mg/mL (117.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.87 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3462 mL | 11.7308 mL | 23.4615 mL | 58.6538 mL |
| 5 mM | 0.4692 mL | 2.3462 mL | 4.6923 mL | 11.7308 mL | |
| 10 mM | 0.2346 mL | 1.1731 mL | 2.3462 mL | 5.8654 mL | |
| 15 mM | 0.1564 mL | 0.7821 mL | 1.5641 mL | 3.9103 mL | |
| 20 mM | 0.1173 mL | 0.5865 mL | 1.1731 mL | 2.9327 mL | |
| 25 mM | 0.0938 mL | 0.4692 mL | 0.9385 mL | 2.3462 mL | |
| 30 mM | 0.0782 mL | 0.3910 mL | 0.7821 mL | 1.9551 mL | |
| 40 mM | 0.0587 mL | 0.2933 mL | 0.5865 mL | 1.4663 mL | |
| 50 mM | 0.0469 mL | 0.2346 mL | 0.4692 mL | 1.1731 mL | |
| 60 mM | 0.0391 mL | 0.1955 mL | 0.3910 mL | 0.9776 mL | |
| 80 mM | 0.0293 mL | 0.1466 mL | 0.2933 mL | 0.7332 mL | |
| 100 mM | 0.0235 mL | 0.1173 mL | 0.2346 mL | 0.5865 mL |